Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.


Clinical Trial Description

For years Fluorouracil was the established treatment for pancreatic cancer with median survival times up to 8 months. Since 1997 Gemcitabine is also a standard therapy with in comparison to Fluorouracil a significant better clinical benefit.

But after progression of the disease under a palliative first-line therapy there is no established second line therapy for pancreatic cancer.

So the purpose of this study is to test the combination of Oxaliplatin and Docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy to get a reasonable second line concept. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00690300
Study type Interventional
Source University of Ulm
Contact Thomas Seufferlein, Prof. Dr.
Phone 49-345-5572661
Email thomas.seufferlein@medizin.uni-halle.de
Status Recruiting
Phase Phase 2
Start date January 2008
Completion date December 2010

See also
  Status Clinical Trial Phase
Completed NCT01774162 - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration N/A
Completed NCT00930410 - Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor N/A
Completed NCT00377936 - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Phase 2
Terminated NCT00198081 - Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs) Phase 2
Active, not recruiting NCT02905578 - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Phase 2
Completed NCT01446458 - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Phase 1
Recruiting NCT02789371 - Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions N/A
Unknown status NCT00683358 - Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer Phase 1/Phase 2
Terminated NCT00683085 - Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer Phase 1/Phase 2
Not yet recruiting NCT03803930 - Comparing of a 22G EUS Procore Fine Needle Biopsy Device and a 20G EUS Procore Fine Needle Biopsy Device N/A
Completed NCT02681796 - Epidural Analgesia Use in Pancreatic Resections Phase 1
Recruiting NCT02327065 - Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion N/A
Completed NCT01693419 - S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer Phase 2